Loading clinical trials...
Loading clinical trials...
The anaplastic lymphoma kinase gene(ALK) is mutated approximately 5% of non-small cell lung cancers. Testing for this gene is important because there are drugs known as ALK inhibitors that have been s...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
British Columbia Cancer Agency
Collaborators
NCT05692635 · Brain Metastases, Nonsmall Cell Lung Cancer Stage III
NCT05283330 · Cervical Cancer, Breast Cancer, and more
NCT04253964 · Nonsmall Cell Lung Cancer, Performance Status
NCT06228482 · Metastatic Nonsmall Cell Lung Cancer
NCT05863052 · Immune Checkpoint Inhibitors, Metastatic Solid Tumor, and more
BC Cancer Agency-Abbotsford Centre
Abbotsford British Columbia, British Columbia
BC Cancer Agency-Centre for the Southern Interior
Kelowna, British Columbia
Lions Gate Hospital
North Vancouver, British Columbia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions